Ocular Therapeutix Inc (OCUL)

9.02 +0.19 (+2.15%) USD  |  NASDAQ  |  Nov 25, 14:57
More

Ocular Therapeutix Debt to Equity Ratio: 0.1926 for Sept. 30, 2024

Debt to Equity Ratio Chart

Historical Debt to Equity Ratio Data

View and export this data back to 2014. Upgrade now.
Date Value
September 30, 2024 0.1926
June 30, 2024 0.1777
March 31, 2024 0.1629
December 31, 2023 0.8222
September 30, 2023 9.409
June 30, 2023 17.94
March 31, 2023 5.631
December 31, 2022 1.526
September 30, 2022 1.154
June 30, 2022 0.8008
March 31, 2022 0.6524
December 31, 2021 0.5845
September 30, 2021 0.5819
June 30, 2021 0.6261
March 31, 2021 0.5757
December 31, 2020 0.6509
September 30, 2020 -11.87
June 30, 2020 9.631
March 31, 2020 -4.725
December 31, 2019 -13.58
September 30, 2019 4.256
June 30, 2019 5.909
Date Value
March 31, 2019 1.866
December 31, 2018 0.691
September 30, 2018 0.3112
June 30, 2018 0.3418
March 31, 2018 0.3474
December 31, 2017 0.689
September 30, 2017 0.4988
June 30, 2017 0.371
March 31, 2017 0.2773
December 31, 2016 0.3008
September 30, 2016 0.2496
June 30, 2016 0.2194
March 31, 2016 0.1917
December 31, 2015 0.1705
September 30, 2015 0.1531
June 30, 2015 0.1379
March 31, 2015 0.2872
December 31, 2014 0.2533
September 30, 2014 0.2252
June 30, 2014 -0.2114
March 31, 2014 0.1797

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

-13.58
Minimum
Dec 2019
17.94
Maximum
Jun 2023
1.047
Average
0.6385
Median

Debt to Equity Ratio Benchmarks

4D Molecular Therapeutics Inc 0.00
NovaBay Pharmaceuticals Inc 0.0476
Palatin Technologies Inc --
iBio Inc --
Theriva Biologics Inc --

Debt to Equity Ratio Related Metrics

Total Assets (Quarterly) 490.37M
Total Liabilities (Quarterly) 138.35M
Shareholders Equity (Quarterly) 352.02M
Current Ratio 13.01
Net Debt Paydown Yield -0.18%